Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.220
-0.090 (-2.09%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Cytek Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 65.67 | 90.85 | 98.72 | 167.3 | 296.6 | 364.62 |
Short-Term Investments | 196.56 | 170.68 | 179.15 | 95.11 | 44.55 | - |
Cash & Short-Term Investments | 262.23 | 261.53 | 277.86 | 262.41 | 341.15 | 364.62 |
Cash Growth | -1.28% | -5.88% | 5.89% | -23.08% | -6.44% | 120.67% |
Accounts Receivable | 51.9 | 62.51 | 60.59 | 55.93 | 48.86 | 29.76 |
Inventory | - | - | - | 60.88 | 48.15 | 32.17 |
Other Current Assets | 15.38 | 19.53 | 14.1 | 12.85 | 15.85 | 5.18 |
Total Current Assets | 379.3 | 392 | 396.45 | 392.06 | 454.02 | 431.73 |
Net Property, Plant & Equipment | 31.11 | 29.32 | 28.13 | 29.26 | 27.57 | 5.85 |
Other Intangible Assets | 15.7 | 16.82 | 20.13 | 23.08 | 4.33 | 4.74 |
Goodwill | 16.69 | 16.7 | 16.66 | 16.18 | 10.14 | 10.14 |
Other Long-Term Assets | 6.31 | 6.7 | 38.13 | 33.87 | 23.42 | 10.84 |
Total Assets | 449.11 | 461.54 | 499.5 | 494.46 | 519.48 | 463.31 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 6.74 | 6.41 | 5.53 | 3.03 | 4.81 | 3.03 |
Accrued Expenses | 19.78 | 23.42 | 21.44 | 20.04 | 21.13 | 15.25 |
Unearned Revenue | 30.03 | 28.5 | 25.49 | 22.7 | 12.99 | 7.08 |
Other Current Liabilities | 24.38 | 19.47 | 15.2 | 10.46 | 10.12 | 7.82 |
Total Current Liabilities | 80.94 | 77.8 | 67.66 | 56.23 | 49.04 | 33.18 |
Long-Term Debt | 0.39 | 0.53 | 1.05 | 1.65 | 2.27 | - |
Long-Term Leases | 13.44 | 14.04 | 7.55 | 9.48 | 12.31 | - |
Other Long-Term Liabilities | 26.71 | 27.43 | 27.5 | 34.04 | 30.31 | 24.74 |
Total Long-Term Liabilities | 40.53 | 42 | 36.1 | 45.17 | 44.89 | 24.74 |
Total Liabilities | 121.47 | 119.8 | 103.76 | 101.39 | 93.93 | 57.92 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.13 | 0.13 | 0.13 | 0.13 | 0.14 | 0.13 |
Additional Paid-in Capital | 445.75 | 441.11 | 430.79 | 423.39 | 442.89 | 423.63 |
Accumulated Other Comprehensive Income | 2.37 | 2.24 | 0.02 | -1.28 | -0.7 | 0.9 |
Retained Earnings | -120.6 | -101.74 | -35.2 | -29.18 | -17.03 | -19.61 |
Total Common Shareholders' Equity | 327.64 | 341.74 | 395.74 | 393.06 | 425.3 | 405.04 |
Minority Interest | - | - | - | - | 0.25 | 0.34 |
Shareholders' Equity | 327.64 | 341.74 | 395.74 | 393.06 | 425.55 | 405.39 |
Total Liabilities & Equity | 449.11 | 461.54 | 499.5 | 494.46 | 519.48 | 463.31 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 13.83 | 14.57 | 8.6 | 11.13 | 14.58 | 0 |
Net Cash (Debt) | 248.4 | 246.96 | 269.26 | 251.28 | 326.57 | 364.62 |
Net Cash Growth | -3.44% | -8.28% | 7.15% | -23.05% | -10.44% | 120.67% |
Net Cash Per Share | 1.94 | 1.93 | 2.06 | 1.86 | 2.36 | 4.47 |
Book Value | 327.64 | 341.74 | 395.74 | 393.06 | 425.3 | 405.04 |
Book Value Per Share | 2.56 | 2.68 | 3.03 | 2.91 | 3.07 | 4.97 |
Tangible Book Value | 295.25 | 308.22 | 358.95 | 353.8 | 410.82 | 390.16 |
Tangible Book Value Per Share | 2.31 | 2.41 | 2.75 | 2.62 | 2.96 | 4.78 |